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Background: Hemoglobin (Hb) variability is a common occurrence in hemodialysis patients treated with
erythropoiesis-stimulating agents. High amplitude fluctuations have been associated with greater risk of morbidity
and mortality.
Methods: This prospective, single centre pilot observational study was conducted over a 3-month period in daily
practice patterns, to assess per-dialysis events and inter-dialysis complications that could interfere with erythropoi-
esis in patients undergoing hemodialysis.
Results: Mean Hb levels remained stable in the 78 evaluable patients, as did darbepoetin alfa (DA) doses, including
in patients suffering from diabetes or cardiac affections. In total, an average of 7.7 events / patient / month
occurred, but no significant relationship with Hb excursions was shown.
Conclusion: The observation of 7.7 events per patient per month suggests a careful monitoring of Hb and DA
dosing every other week, in order to maintain Hb level within the target.
Keywords: Darbepoetin alfa, Hemodialysis, Hemoglobin cycling, Inter-dialysis complications, Per-dialysis eventsBackground
Anemia is an important and common complication in
patients with end-stage renal disease treated with
chronic maintenance hemodialysis (HD). Its impact on
cardiovascular outcomes, quality of life and even survival
has been widely assessed. As a result, throughout the
years, several guidelines have defined the targets in
hemoglobin (Hb) levels that need to be achieved in HD
patients [1-5]. These have been recently modified by the
KDIGO clinical practice guidelines for anemia in chronic
kidney disease (CKD) [6]. Treatment with erythropoietin
stimulating agents (ESAs) has been a major advance in
the management of this problem. There is, however, a
great difference between treatment and physiological
erythropoietic biology, in so far as ESAs are administered
episodically, generating important changes in erythropoi-
etin – and hence – Hb levels [7]. This phenomenon,* Correspondence: jacques.rottembourg@wanadoo.fr
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distribution, and reproduction in any mediumwhich is commonly encountered in ESA-treated patients
[8,9], is known as Hb cycling. It can be defined as cyclical
increases and decreases of measured Hb levels in individ-
ual patients [7]. Its consequences are not fully known,
however it may be accepted that Hb cycling can result in
fluctuations of the oxygen carried to the tissues, and re-
peated episodes of relative ischemia in vital organs can
lead to organ dysfunction or injury. Indeed, high ampli-
tude swings have been found to be associated with
greater risk of mortality and hospitalization [10].
Apart from anemia management, several factors can
be accounted for causing Hb cycling: amongst others, in-
flammatory and infectious diseases, blood loss, hyper-
parathyroidism and hospitalizations [7-9]. On the other
hand, little is known about dialysis-related incidents,
whether they occur during or between HD sessions.
This prospective, single-center pilot observational
study was conducted over a 3-month period, to assess
the number and importance of per-dialysis events and
inter-dialysis complications that could possibly interfere
with erythropoiesis in patients undergoing hemodialysis.entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Patients were treated according to routine clinical prac-
tices in the unit. As required by law, no formal approval
was required by the independent ethic committee, and
patients provided written informed consent prior to
study entry [11]. All patients treated in our center were
included for 12 weeks in the study. They were prescribed
regular HD on Integra-Hospal generators for 3.5 to
4 hours three times weekly. Vascular access was assessed
by double arterio-venous fistula punctures in all patients.
On start of the dialysis session, each patient received a
0.2 to 0.6 ml injection of nadroparin calcium, a low mo-
lecular weight heparin. High and medium permeability
membranes were used throughout the study and were
unchanged for each patient. Darbepoetin alfa (DA) injec-
tions were performed every other week (during the first
dialysis session of the week) in the venous injection site
before the drip chamber on the venous line (Pivipol
Hospal). Any change in the dosing of DA required a
follow-up of four Hb measurements, and the adaptation
was made by one physician who knows the previous
doses and the clinical program of the patient: if, on 4 Hb
values, one was outside of the target, nothing was chan-
ged; if 2 or 3 values were outside of the target, the dos-
ing was adapted depending the amplitude. Intravenous
(IV) iron (iron sucrose [V]) was injected, if necessary,
once a week during the second dialysis session at a dose
ranging from 25 to 100 mg.
The follow-up conditions were those of daily practice,
and the protocol ensured that no complementary visits
or biological assessments would be performed outside
the usual HD follow-up. Biological parameters such as
Hb, calcium, phosphorus, urea, creatinine and DA dose,
were assessed every other week; iron dose was recorded
every week. Other parameters, and especially C-reactive
protein, PTH and nutritional parameters [albumin and
normalized protein catabolic rate (nPCR)] were assessed
at baseline and on week 12; dialysis adequacy was
assessed at the same period by Kt/V and urea reduction
ratio (URR). Hb variation was defined as a ≥ 1 g/dl Hb
excursion above or under baseline value and a ≥ 4 week-
duration.
Upon each dialysis session, per-dialysis events, such as
fistula bleeding, puncture problems, hypotension, clotting
in lines or dialyzer, blood loss, and delayed coagulation,
were recorded by the nurses on specific questionnaires.
Physicians assessed each week inter-dialysis complications,
mainly cardiovascular, digestive, infectious, hemorrhagic,
and vascular access, by three means of consultation: face
to face, by phone, and, when in doubt, by consulting the
family.
Descriptive statistics were applied for quantitative vari-
ables, and results are reported with mean values and
standard deviations; median values and ranges are alsoprovided when appropriate, owing to dispersion of
values. A uni-variate analysis was performed to assess if
there is an association between events (per-dialysis and
inter-dialysis) and hemoglobin excursion. The evaluable
population comprised patients who attended every dialy-
sis session during this prospective study; patients
who were absent for any reason (vacation, prolonged
hospitalization, graft, death) were excluded.
Results
Evaluable population
Out of 100 patients undergoing HD in the center, 78
attended every dialysis session for 3 months, and there-
fore constituted the evaluable population. 22 patients
were excluded because they did not attend all the dialy-
sis sessions: 2 patients died, 4 were grafted, 7 were hos-
pitalized for 3 to 28 days, and 9 went in vacation. The
demographics and characteristics of these 78 patients, at
baseline, were shown in Table 1. More than two-thirds
were males, and the mean (± SD) age was 59 (± 16.6)
years. They had been undergoing dialysis for a median
time of almost three years (34.5 months). Nearly all of
them (94.9%) suffered from hypertension, and 47.4%
from cardiac insufficiency. Medical history and current
treatments at baseline are shown in Table 2.
Hemoglobin and DA dose, iron dose
Over the study period, mean Hb levels remained stable
in the evaluable population, as did DA doses (Table 3).
Throughout the study, approximately 80% of patients
had levels ≥ 11 g/dl. Similar findings were reported
for patients suffering from cardiac affections or from
Table 2 Current history and medical treatments at
baseline
Characteristics Evaluable patients (n = 78)
Medical History, n (%)
Hypertension 74 (94.9)
Cardiac insufficiency 37 (47.4)
NYHA II 6 (16.2)
NYHA III 25 (67.6)
NYHA IV 6 (16.2)
Coronary artery disease 22 (28.2)
Myocardial infarction 5 (6.4)
Stroke 7 (9.0)
Limb arteritis 27 (35.5)
Hepatitis 20 (25.6)
Cancer 10 (12.8)
Current treatments, n (%)
ACE inhibitors and/or ARBs 23 (29.5)
VKAs, aspirin, platelet aggregation inh. 37 (47.4)
Dyslipidemia treatment 61 (78.2)
Hepatitis treatment 7 (9.0)
Cancer treatment 17 (21.8)
NYHA: New York Heart Association; ACE: angiotensin converting enzyme; ARBs:
angiotensin receptor blockers; VKAs: vitamin K antagonists.
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very few, if any, changes in DA doses during the 3-
months duration of the study: 46% of patients did not
require any change, whilst 42% only required one change
(Figure 1). Twelve patients require more than one adap-
tation of DA doses during the study: these patients are
the one who suffered of the most events. Seven patients
did not receive any DA treatment; as a whole, their Hb
levels were slightly higher than those of the patients re-
ceiving DA: median Hb was 12.0 g/dl at baseline, and
remained stable over the 3-month period, even rising toTable 3 Hemoglobin concentrations and DA doses over time
Variables Baseline W2 W4
Hemoglobin (g/dl)
Mean (SD) 11.8 (1.34) 11.8 (1.25) 11.9 (1
Median 11. 7 11.6 12.1
≥ 11 g/dl (%) 79.5 79.2 82.1
Weekly DA dose (μg/week)
Mean (SD) 47.7 (40.2) 45.9 (40.8) 45.6 (4
Median 30 30 30
Weighted weekly DA dose
(μg/week/kg)
Mean (SD) 0.76 (0.7) 0.75 (0.8) 0.74 (0
Median 0.48 0.46 0.47a median of 13.2 g/dl in the last two weeks. Sixty eight
patients received IV iron at a mean (± SD) dosage of 59
(± 35) mg per week.
Biological variables
Iron status remained stable throughout the study
(Table 5). Serum ferritin was ≥ 100 μg/l in almost 95% of
patients, both at baseline, and at the end of the study. C-
reactive protein at baseline, week 6 and week 12 was <
10 mg/l in a majority of patients (76.2%, 84.5.0% and
89.8% respectively). During the 3-month study period,
nutritional variables also remained stable in the evalu-
able population (Table 5), as well as in cardiac and dia-
betic subgroups. Dialysis adequacy was achieved with a
mean (SD) urea reduction ratio between 0.73(0.07) at
baseline and 0.70 (0.07) at the end of the study and Kt/V
at 1.49 (0.39) and 1.35 (0.34) respectively. Serum cal-
cium, phosphorus and PTH were maintained in the
current guidelines.
Per-dialysis events and inter-dialysis complications
Intercurrent events over the study duration, i.e. 2,808
dialysis sessions, are summarized in Table 6. As ex-
pected, most per-dialysis events were related to blood
circuit, and almost all patients experienced at least once
clotting (97.4%) or blood loss and delayed coagulation
(93.6%). Hypotensive episodes occurred at least once in
84.6% of patients. Events related to HD technique, such
as puncture problems and fistula bleeding, occurred less
frequently with a total of 149 and 38 respectively, and
concerned one half and one third of patients
respectively.
Vascular access complications were also less frequent,
occurring in 21.8% of patients. The most frequent inter-
dialysis complications were digestive (76 experienced by
59% of patients), and infectious (83 experienced by
57.7%). There were no relationship between hemoglobin
excursions and intercurrent events (Table 7).- Evaluable population (n = 78)
W6 W8 W10 W12
.27) 11.9 (1.43) 11.8 (1.57) 12.0 (1.35) 11.8 (1.47)
11.8 11.7 11.9 11.8
78.1 73.0 81.9 80.5
0.8) 43.2 (39.6) 42.7 (39.3) 42.2 (39.6) 40.9 (38.5)
30 30 30 30
.8) 0.70 (0.7) 0.70 (0.7) 0.70 .8) 0.67 (0.7)
0.42 0.42 0.41 0.39
Table 4 Hemoglobin concentrations and DA doses over time – Cardiac and diabetic patients
Variables Cardiac patients (n = 46) Diabetic patients (n = 21)
Baseline W6 W12 Baseline W6 W12
Hemoglobin (g/dl)
Mean (SD) 11.9 (1.5) 12.1 (1.5) 11.7 (1.7) 12.0 (0.7) 11.9 (0.8) 11.7 (1.0)
Median (range) 11.9 (6.8-15.2) 11.9 (9.3-17.4) 11.8 (6.4-17.0) 11.9 (11.0-13.2) 11.7 (10.6-14.0) 11.8 (9.5- 13.2)
Weekly DA dose
(μg/week)
Mean (SD) 52.9 (44.0) 44.7 (40.1) 43.3 (39.5) 38.6 (33.9) 35.3 (33.0) 29.5 (22.1)
Median (range) 40.0 (10.0-200.0) 30.0 (10.0-200.0) 30.0 (10.0-200.0) 30.0 (10.0-150.0) 25.0 (10.0-150.0) 20.0 (10.0-100.0)
Weighted weekly DA dose
(μg/week/kg)
Mean (SD) 0.8 (0.7) 0.7 (0.7) 0.7 (0.7) 0.5 (0.5) 0.5 (0.5) 0.4 (0.3)
Median (range) 0.53 (0.2-3.3) 0.43 (0.2-3.3) 0.45 (0.1-3.3) 0.38 (0.2-2.4) 0.38 (0.2-2.4) 0.36 (0.1-1.5)
Table 5 Biological variables over time – Evaluable
population (n = 78)
Variables Baseline Week 12
Ferritin (μg/l)
Mean (SD) 478 (289.4) 468 (265.4)
Median 456 443
< 100 μg/l, n (%) 4 (5.1) 4 (5.2)
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curred, that might interfere with erythropoiesis. There is
no correlation between per-dialysis events and hemoglobin
excursions (r = 0.18, p < 0.52) and inter-dialysis events and
hemoglobin excursions (r = 0.21, p < 0.51).
Discussion and conclusions
Anemia, a common complication in patients with end-
stage renal disease on dialysis has been shown to in-
crease the risk of morbidity and increased mortality, and
alters quality of life. Ebben and colleagues studied
152,846 Medicare hemodialysis patients and defined six
patients groups on the basis of hemoglobin level fluctu-
ation [10]. The consistently low group (Hb < 11 g/dl)
had the highest percentage of hospitalizations and the
highest number of co-morbid conditions. On the other
hand, the CHOIR trial, in patients not on dialysis,
showed that targeting a hemoglobin level of 13.5 g/dl
was associated with a significantly increased risk of a
composite endpoint of death, myocardial infarction,
hospitalization for congestive heart failure, and stroke,Figure 1 Proportions of patients requiring DA dose changes
over time.without any significant improvement in quality of life
[12]. A same figure was observed on hemodialysis in the
Normal Hematocrit Study [13]. It appears that both low
and high Hb levels are associated with increased mortal-
ity risk, in a U-shaped or inverse J-curve relationship
[14]. Somewhat conflicting results have been published,
however: in a 2-year duration study of 5,037 European
HD patients, Eckard and colleagues determined Hb vari-
ability, and concluded that, although it is frequently seen
in these patients, it does not independently predict mor-
tality [15].Transferrin saturation (%)
Mean (SD) 40 (9.2) 41 (8.9)
Median 41 41
Albumin (g/l)
Mean (SD) 38.9 (4.4) 40.7 (4.5)
Median 38.7 40.7
nPCR (g/kg/day)
Mean (SD) 0.9 (0.2) 0.8 (0.2)
Median 0.9 0.8
C-reactive protein (mg/l), n (%)
Mean (SD) 9.8 (13.5) 6.4 (10.3)
< 10 mg/l, mean(SD), (%) 4.4 (2.0), (76.4) 4.1 (1.8), (89.9)
≥ 10 mg/l, mean(SD), (%) 27.1 (19.5), (23.6) 29.8 (25.0), (10.1)
nPCR: normalized protein catabolic rate.
Table 6 Intercurrent events during the 3-month study
Events Total number of events % of patients with ≥ 1 event Mean number of events/patient/month
Peridialysis events
Fistula bleeding 38 33.3 0.2
Puncture problem 149 50.0 0.6
Hypotension 308 84.6 1.3
Clotting (lines, dialyzer) 596 97.4 2.6
Blood loss & delayed coagulation 425 93.6 1.8
Interdialysis complications
Cardiovascular 48 34.6 0.2
Digestive 76 59.0 0.3
Infectious 83 57.7 0.4
Hemorrhagic 52 41.0 0.2
Vascular access 20 21.8 0.1
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patient-related factors such as per-dialysis events, inter-
dialysis events and co-morbid conditions could influence
the degree of Hb variability in patients undergoing HD,
if the monitoring of Hb and the dosing of DA are done
with an interval exceeding two weeks. A total of 1516
per-dialysis events such as fistula bleeding, puncture
problems, hypotension, clotting in the lines or dialyzer
or delayed coagulation resulting in blood loss were ob-
served along with 279 inter-dialysis events such as car-
diovascular, infectious hemorrhagic and vascular access
complications that did not lead to hospitalizations, or
for no more than two days. This resulted in a mean 7.7
events per month per patient potentially interfering with
erythropoiesis.
Defining an optimal level for Hb patients with CKD is
therefore difficult. This may explain why guidelines have
evolved during the past decade, recommending a target
of 10 to12 g/dl for the latest KDOQI guidelines [16,17],
which is narrower for ERBP (11–12 g/dl) [18], and much
higher than the new KDIGO (9.5-11.5 g/dl) [6].
A small number of HD patients, however, have normal




Events (N = 78) (N = 46) (N = 32)
Cardiovascular complication 27 (34.6%) 17 (37%) 10 (31.3%)
Digestive tract complication 46 (59%) 27 (58.7%) 19 (59.4%)
Infectious complication 45 (57.7%) 26 (56.5%) 19 (59.4%)
Hemorrhagic complication 32 (41.0%) 16 (34.8%) 16 (50.0%)
Access complication 17 (21.8%) 12 (26.1%) 5 (15.6%)
*Hemoglobin excursion: variation ≥1 g/dl in up or down and
duration ≥4 weeks.45 non anemic HD patients was compared to a control
group of 205 HD patients on ESA therapy [19]. Absence
of anemia was more frequent in men and younger pa-
tients with long-term renal replacement therapy, in pa-
tients with HCV + liver disease and adult polycystic
kidney disease, associated with increased endogenous
erythropoietin production and renal and hepatic cysts.
In our study, 7 of the 78 evaluable patients did not re-
ceive any ESA therapy, 3 of them had a polycystic kidney
disease, 3 were diabetics and one had a nephrosclerosis.
More than a set target level, however, fluctuations in
Hb levels have been shown to be associated with co-
morbid situations. This frequent phenomenon, known as
hemoglobin cycling, can be defined as fluctuations over
time in measured Hb levels, increasing above or decreas-
ing below the target and reversing direction [7]. Appar-
ently stable mean Hb levels in an overall study
population can hide the occurrence of intra-individual
variability in many patients. In a retrospective data ana-
lysis of 281 HD patients receiving ESAs, an occurrence
of Hb cycling in 90% of patients has been reported [9].
Lacson and colleagues reported important fluctuations
over time, with only 5% of ESRD patients in the target
range during a 6-month period observation [20]. In an-
other retrospective study, undertaken in the Netherlands,
none of the 97 ESA-treated patients had Hb levels stable
within the target range over a one-year period [21]. In our
present study, we report stable levels of hemoglobin as a
whole in the evaluable population, as well as in the cardiac
and diabetic subgroups, during the whole study period.
However 54% of the patients needed at least one change in
darbepoetin alfa dose, to compensate Hb fluctuations out-
side the target level. In our unit, over the last few years, the
median number of darbepoetin alfa dose changes per year is
about three [22].
Numerous causes have been identified that can result
in Hb cycling. Some are patient-related, such as age
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conditions, e.g. inflammatory states or infections [10],
levels of parathyroid hormone, and concurrent hematologic
disorders. In HD patients, red blood cells have a short
circulating half-life, due to fluctuations in erythropoi-
etin levels, and this is a component of variability in Hb
levels [24].
Other causes of Hb variability are drug-related: ESAs
have been a major advance in anemia management, but
also contribute to Hb cycling, and compounds pharma-
cokinetics, dosing and frequency of administration gen-
erate substantial changes in erythropoiesis [25-27]. For
Portoles, long-acting ESA, darbepoetin alfa, achieved
better Hb stability than short-acting ESA [28]. Iron
homeostasis also plays an important role in anemia
management [29]. If the etiology of Hb variability is not
easily discerned, erythropoietic hyporesponsiveness must
be envisaged and evaluated, and all efforts brought to
reaching stability [30,31].
Hb testing procedures, practice patterns and reim-
bursement policies can also contribute to Hb fluctua-
tions. Publications have mentioned center-effects: a
retrospective observational study conducted on the US
Renal Data System (USRDS) in 2000 and 2001 identified
a wide center variation in hematocrit, with a mean dif-
ference of 3.06 between the poorest versus the best per-
forming units [32].
All these factors can thus contribute to intra-patient
variability. Amongst them, intercurrent events, such as
inter-dialysis complications and per-dialysis events have
been little studied. De Francisco and colleagues carried
out a post-hoc analysis of Hb concentrations on the
pooled records of 5,592 HD patients included in Phase
3b trials on the efficacy and safety of darbepoetin alfa
for the management of anemia [23]. The intra-patient
variability was significantly greater in the presence of
infection or inflammation, blood transfusion, or hospi-
talization including for cardiovascular causes. Little is
known about the per-dialysis events which are the most
frequent events observed in the HD population: com-
pared to patients treated by peritoneal dialysis, the Hb
level is less stable in patients treated by HD [33] and the
requirement of ESAs doses much higher in the HD
population [34,35]. Moreover inter dialysis hypotension
episodes, which are one of the most frequent events, are
known to disturb hemoglobin stability [36], and patients
suffering of frequent intradialytic hypotensive episodes
present a hemoglobin level lower than that of the stable
patients [37].
It has been advised that strategies to minimize Hb cyc-
ling should focus on individualizing targets for the pa-
tients. Targets defined by the guidelines are convenient
for most patients. However, authors have recommended
that the therapeutic decision should center on what Hbis most appropriate at a “safe ESA dose”, even if it means
a target of 12 to 13 g/dl [38].
In our experience, in order to achieve and stabilize Hb
levels within a safe range, we use moderate DA doses
and address the ongoing iron needs of the patients, now
injected on the same Q2W basis than DA [39]. Monitor-
ing both Hb and DA dosing every other week appears to
be the most sensible way to achieve this goal. However,
our study is a pilot study, and needs to be confirmed by
wider multicenter trials.
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